PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29258184-5 2017 Recent studies have demonstrated that the endogenously produced peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist cyclic phosphatidic acid (cPA), which is structurally similar to LPA, inhibits cancer cell invasion and metastasis in vitro and in vivo. cpa 162-165 peroxisome proliferator activated receptor gamma Homo sapiens 64-112 29990859-2 2018 On the other hand, cyclic phosphatidic acid (cPA), similar in structure to AGP, can negatively regulate PPARgamma. cpa 45-48 peroxisome proliferator activated receptor gamma Homo sapiens 104-113 29258184-5 2017 Recent studies have demonstrated that the endogenously produced peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist cyclic phosphatidic acid (cPA), which is structurally similar to LPA, inhibits cancer cell invasion and metastasis in vitro and in vivo. cpa 162-165 peroxisome proliferator activated receptor gamma Homo sapiens 114-123 29258184-6 2017 We recently observed that cPA negatively regulates PPARgamma function by stabilizing the binding of the co-repressor protein, a silencing mediator of retinoic acid, and the thyroid hormone receptor. cpa 26-29 peroxisome proliferator activated receptor gamma Homo sapiens 51-60 29258184-7 2017 We also showed that cPA prevents neointima formation, adipocyte differentiation, lipid accumulation, and upregulation of PPARgamma target gene transcription. cpa 20-23 peroxisome proliferator activated receptor gamma Homo sapiens 121-130 25013374-8 2014 Interestingly, treatment with AGP increased the expression and secretion of endogenous interleukin (IL)-6 and IL-8; however, this effect was inhibited when HCAECs were cotreated with cPA or the synthetic peroxisome proliferator-activator receptor gamma (PPARgamma) antagonist T0070907. cpa 183-186 peroxisome proliferator activated receptor gamma Homo sapiens 254-263 26007326-6 2015 Our previous result indicates that cyclic phosphatidic acid (cPA), one of bioactive lipids, potently suppresses neointima formation by inhibiting the activation of peroxisome proliferator-activated receptor gamma (PPARgamma). cpa 61-64 peroxisome proliferator activated receptor gamma Homo sapiens 164-212 26007326-6 2015 Our previous result indicates that cyclic phosphatidic acid (cPA), one of bioactive lipids, potently suppresses neointima formation by inhibiting the activation of peroxisome proliferator-activated receptor gamma (PPARgamma). cpa 61-64 peroxisome proliferator activated receptor gamma Homo sapiens 214-223 23008752-3 2012 We encapsulated cPA in gelatin-based hydrogels and examined its ability to inhibit the viability and migration of HT-29 and DLD-1 cells in vitro and the LPA-induced activity of the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma). cpa 16-19 peroxisome proliferator activated receptor gamma Homo sapiens 202-250 23008752-3 2012 We encapsulated cPA in gelatin-based hydrogels and examined its ability to inhibit the viability and migration of HT-29 and DLD-1 cells in vitro and the LPA-induced activity of the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma). cpa 16-19 peroxisome proliferator activated receptor gamma Homo sapiens 252-261 23008752-5 2012 Accordingly, cPA-hydrogel microspheres substantially inhibited LPA-induced PPARgamma activity and cell growth and migration compared with that of cells cultured with cPA alone. cpa 13-16 peroxisome proliferator activated receptor gamma Homo sapiens 75-84 20932931-2 2010 cPA is a specific, high-affinity antagonist of peroxisome proliferator-activated receptor gamma (PPARgamma); however, the molecular mechanism by which cPA inhibits cellular proliferation remains to be clarified. cpa 0-3 peroxisome proliferator activated receptor gamma Homo sapiens 47-95 20932931-2 2010 cPA is a specific, high-affinity antagonist of peroxisome proliferator-activated receptor gamma (PPARgamma); however, the molecular mechanism by which cPA inhibits cellular proliferation remains to be clarified. cpa 0-3 peroxisome proliferator activated receptor gamma Homo sapiens 97-106 20932931-4 2010 cPA suppressed cell growth, and this effect was reversed by the addition of a PPARgamma agonist. cpa 0-3 peroxisome proliferator activated receptor gamma Homo sapiens 78-87 20932931-5 2010 These results indicate that the physiological effects of cPA are partly due to PPARgamma inhibition. cpa 57-60 peroxisome proliferator activated receptor gamma Homo sapiens 79-88 20932931-6 2010 Our results identify PPARgamma as a molecular mediator of cPA activity in HT-29 cells, and suggest that cPA and the PPARgamma pathway might be therapeutic targets in the treatment of colon cancer. cpa 58-61 peroxisome proliferator activated receptor gamma Homo sapiens 21-30 20932931-6 2010 Our results identify PPARgamma as a molecular mediator of cPA activity in HT-29 cells, and suggest that cPA and the PPARgamma pathway might be therapeutic targets in the treatment of colon cancer. cpa 104-107 peroxisome proliferator activated receptor gamma Homo sapiens 21-30 20816085-1 2010 A recent study in Molecular Cell (Tsukahara et al., 2010) identifies cyclic phosphatidic acid (CPA) as a naturally occurring PPARgamma antagonist that can be generated from lysophospholipids by signal-dependent activation of phospholipase D2. cpa 95-98 peroxisome proliferator activated receptor gamma Homo sapiens 125-134 20816085-2 2010 This endogenous CPA regulates PPARgamma functions required for adipogenesis, glucose homeostasis, and vascular wall biology. cpa 16-19 peroxisome proliferator activated receptor gamma Homo sapiens 30-39 22693486-3 2012 Recent studies have provided evidence that the endogenously produced PPARgamma antagonist, 2,3-cyclic phosphatidic acid (cPA), which is similar in structure to lysophosphatidic acid (LPA), inhibits cancer cell invasion and metastasis in vitro and in vivo. cpa 121-124 peroxisome proliferator activated receptor gamma Homo sapiens 69-78 22693486-4 2012 We recently observed that cPA negatively regulates PPARgamma function by stabilizing the binding of the corepressor protein, silencing mediator of retinoic acid and thyroid hormone receptor. cpa 26-29 peroxisome proliferator activated receptor gamma Homo sapiens 51-60 22693486-5 2012 We also showed that cPA prevents neointima formation, adipocyte differentiation, lipid accumulation, and upregulation of PPARgamma target gene transcription. cpa 20-23 peroxisome proliferator activated receptor gamma Homo sapiens 121-130 22693486-6 2012 We then analyzed the molecular mechanism of cPA"s action on PPARgamma. cpa 44-47 peroxisome proliferator activated receptor gamma Homo sapiens 60-69 22693486-7 2012 In this paper, we summarize the current knowledge on the mechanism of PPARgamma-mediated transcriptional activity and transcriptional repression in response to novel lipid-derived ligands, such as cPA. cpa 197-200 peroxisome proliferator activated receptor gamma Homo sapiens 70-79